Quantrx Biomedical (Quantrx Biomedical) Debt-to-Equity : -1.00 (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical Debt-to-Equity?

Quantrx Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $2.83 Mil. Quantrx Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Quantrx Biomedical's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $-2.84 Mil. Quantrx Biomedical's debt to equity for the quarter that ended in Sep. 2022 was -1.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Quantrx Biomedical's Debt-to-Equity or its related term are showing as below:

QTXB's Debt-to-Equity is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 0.22
* Ranked among companies with meaningful Debt-to-Equity only.

Quantrx Biomedical Debt-to-Equity Historical Data

The historical data trend for Quantrx Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical Debt-to-Equity Chart

Quantrx Biomedical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-Equity

Get a 7-Day Free Trial

-2.60

-1.33

-1.04

-1.02

-1.00

Quantrx Biomedical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Debt-to-Equity	Get a 7-Day Free Trial															-1.00	-1.00	-1.00	-0.97	-1.00

Competitive Comparison of Quantrx Biomedical's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantrx Biomedical's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Quantrx Biomedical's Debt-to-Equity falls into.

Quantrx Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Quantrx Biomedical's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.637	+	0)	/	-2.641
	=	-1.00

Quantrx Biomedical's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.829	+	0)	/	-2.841
	=	-1.00

Quantrx Biomedical (OTCPK:QTXB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Quantrx Biomedical Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantrx Biomedical (Quantrx Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

10190 SW 90th Avenue, Tualatin, OR, USA, 97062

Website

http://www.quantrx.com

Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.

Executives

Michael S Abrams	director	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco	director	1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk	10 percent owner	229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine	director, 10 percent owner	1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr	director	C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton	officer: V.P. of Diagnostics	209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev	officer: Officer	120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman	officer: Officer	5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming	director, officer: Secretary
Walter W Witoshkin	director, officer: President and CEO	321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc	10 percent owner	5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc	10 percent owner	570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines